Managed Healthcare Executive asked key opinion leaders their thoughts on the drug rebate controversy. Here’s what they said.
Are recent pharma price drops just a response to political pressure or will the momentum last? Managed Healthcare Executive asked industry experts, and here’s what they said.
To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive conducted its annual pharmacy survey during the first quarter of 2018.
Healthcare experts weigh in on the president’s plan to lower drug prices. Here’s what they said.
The International Rare Diseases Research Consortium hopes to develop 200 new drugs for rare diseases by 2020, and it seems as if things are better than on track.
Legislation removes FDA involvement when patients seek experimental medications. Here’s what critics and proponents say.
The goal is to help ensure that prescription drug marketing information for consumers and healthcare providers is truthful and balanced. Here’s what the agency plans to research.
Diabetes drug spending is on the rise, but there are ways to control it.
Director of medication safety and quality for the American Society of Health-System Pharmacists shares how providers can better work with pharmacists to address the opioid epidemic.
More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.